Company Profile
TransCode Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- RNAZ
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.27 USD (+0.47%)
Close
Last updated: August 6, 2026
5.02M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, RNAZ closed up 0.47% at $4.27. No new same-company headline was identified in the current news window.
Company overview
Business overview
TransCode Therapeutics is an RNA-based oncology company focused on microRNA and gene-regulation approaches to cancer. Its story is built around using RNA therapeutics to address difficult tumors.
Geographic Base and Sector Classification
TransCode is headquartered in the United States and listed on NASDAQ. It sits in small-cap oncology biotechnology.
Business Model Characteristics
The company depends on preclinical and early clinical progress, translational confidence, and funding to support a narrow pipeline. Investors usually watch data quality and whether the platform can create a meaningful cancer signal.
Position Within the Biotechnology Landscape
TransCode occupies a niche RNA-oncology position within biotech. It remains a catalyst-sensitive small-cap name because the science still needs to prove itself clinically.
Future catalysts
TransCode’s catalysts are RNA-targeted oncology programs and any update that clarifies whether the delivery approach can still advance. The company still needs human proof.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of TransCode Therapeutics, Inc. (RNAZ)?
TransCode Therapeutics, Inc. (RNAZ) most recently closed at 4.27 USD, a +0.47% move versus the previous session.
What is the market cap of TransCode Therapeutics, Inc. (RNAZ)?
TransCode Therapeutics, Inc. currently has a market capitalization of 5.02M USD on BioPharmSignal.
What does TransCode Therapeutics, Inc. do?
TransCode Therapeutics is an RNA-based oncology company focused on microRNA and gene-regulation approaches to cancer. Its story is built around using RNA therapeutics to address difficult tumors.
On which exchange is RNAZ stock listed?
TransCode Therapeutics, Inc. (RNAZ) is associated with NASDAQ, United States, Biopharma.
What is TransCode?
TransCode’s catalysts are RNA-targeted oncology programs and any update that clarifies whether the delivery approach can still advance.
Which conditions is TransCode Therapeutics, Inc. targeting with TransCode?
TransCode Therapeutics, Inc. is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does TransCode Therapeutics, Inc. describe recent progress with TransCode?
TransCode’s catalysts are RNA-targeted oncology programs and any update that clarifies whether the delivery approach can still advance.
What is Therapeutics?
TransCode Therapeutics is an RNA-based oncology company focused on microRNA and gene-regulation approaches to cancer.